Bezafibrate for the treatment of dyslipidemia in patients with coronary artery disease: 20-year mortality follow-up of the BIP randomized control trial

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Arbel, Yaron ^a   Klempfner, Robert ^a,c   Erez, Aharon ^a   Goldenberg, Ilan ^a,c,d   Benzekry, Sagit ^a   Shlomo, Nir ^c   Fisman, Enrique Z ^b   Tenenbaum, Alexander ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b Cardiovascular Diabetology Research Foundation   (Israel)

^c Israeli Association for Cardiovascular Trials   (Israel)

^d UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Bezafibrate; Cholesterol; Coronary disease; HDL; Lipids; Mortality; Prognosis; Triglycerides

Indexed keywords

BEZAFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; RISK REDUCTION; TREATMENT OUTCOME; BLOOD; CHI SQUARE DISTRIBUTION; COMPLICATION; INTENTION TO TREAT ANALYSIS; ISRAEL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; TIME FACTOR;

AGED; BEZAFIBRATE; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; INTENTION TO TREAT ANALYSIS; ISRAEL; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84959114847     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0332-6     Document Type: Article

References (40)

1. Schwartz GG, Abt M, Bao W, DeMicco D, Kallend D, Miller M, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. J Am Coll Cardiol. 2015;65(21):2267-75. doi: 10.1016/j.jacc.2015.03.544.
2. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322(5908):1702-5. doi: 10.1126/science.1161524.
3. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J. 2013;34(24):1826-33. doi: 10.1093/eurheartj/ehs431.
4. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32-41. doi: 10.1056/NEJMoa1308027.
5. Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22-31. doi: 10.1056/NEJMoa1307095.
6. Tenenbaum A, Klempfner R, Fisman EZ. Hypertriglyceridemia: a too long unfairly neglected major cardiovascular risk factor. Cardiovasc Diabetol. 2014;13:159. doi: 10.1186/s12933-014-0159-y.
7. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 2014;384(9943):626-35. doi: 10.1016/s0140-6736(14)61177-6.
8. Joshi PH, Martin SS, Blumenthal RS. The remnants of residual risk. J Am Coll Cardiol. 2015;65(21):2276-8. doi: 10.1016/j.jacc.2015.03.543.
9. Prevention The Bezafibrate Infarction (BIP) study group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation. 2000;102(1):21-7.
10. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med. 2005;165(10):1154-60. doi: 10.1001/archinte.165.10.1154.
11. Goldbourt U, Brunner D, Behar S, Reicher-Reiss H. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study. Eur Heart J. 1998;19(Suppl H):H42-7.
12. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol. 1993;71(11):909-15.
13. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. Circulation. 1992;86(3):839-48.
14. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol. 2012;11:125. doi: 10.1186/1475-2840-11-125.
15. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341(7):498-511. doi: 10.1056/nejm199908123410707.
16. Arbel Y, Havakuk O, Halkin A, Revivo M, Berliner S, Herz I, et al. Relation of metabolic syndrome with long-term mortality in acute and stable coronary disease. Am J Cardiol. 2015;115(3):283-7. doi: 10.1016/j.amjcard.2014.10.037.
17. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563-74. doi: 10.1056/NEJMoa1001282.
18. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009;32(3):493-8. doi: 10.2337/dc08-1543.
19. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-61. doi: 10.1016/s0140-6736(05)67667-2.
20. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85(1):37-45.
21. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285(12):1585-91.
22. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med. 2010;363(7):692-4 (author reply 4-5).
23. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875-84. doi: 10.1016/s0140-6736(10)60656-3.
24. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-9
25. Goldenberg I, Benderly M, Goldbourt U. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial. J Am Coll Cardiol. 2008;51(4):459-65. doi: 10.1016/j.jacc.2007.09.048.
26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89. doi: 10.1056/NEJMoa0806470.
27. Bianchi C, Del Prato S. Metabolic memory and individual treatment aims in type 2 diabetes-outcome-lessons learned from large clinical trials. Rev Diabet Stud RDS. 2011;8(3):432-40. doi: 10.1900/rds.2011.8.432.
28. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-91. doi: 10.1056/NEJMoa0706245.
29. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421
30. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol. 2006;48(3):438-45. doi: 10.1016/j.jacc.2006.04.070.
31. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol. 2012;60(10):875-81. doi: 10.1016/j.jacc.2012.07.007.
32. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889-934. doi: 10.1016/j.jacc.2013.11.002.
33. Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, et al. Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol. 2014;13:26. doi: 10.1186/1475-2840-13-26.
34. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969-89. doi: 10.1210/jc.2011-3213.
35. Madrid-Miller A, Moreno-Ruiz LA, Borrayo-Sanchez G, Almeida-Gutierrez E, Martinez-Gomez DF, Jauregui-Aguilar R. Ipact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial. Cir Cir. 2010;78(3):229-37.
36. Klempfner R, Goldenberg I, Fisman EZ, Amit U, Haitovich A, Matetzky S, et al. Bezafibrate treatment is associated with a reduced rate of re-hospitalization in smokers after acute coronary syndrome. Cardiol J. 2014;21(4):364-9. doi: 10.5603/CJ.a2013.0127.
37. Tenenbaum A, Medvedofsky D, Fisman EZ, Bubyr L, Matetzky S, Tanne D, et al. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One. 2012;7(4):e35298. doi: 10.1371/journal.pone.0035298.
38. Klempfner R, Goldenberg I, Fisman EZ, Matetzky S, Amit U, Shemesh J, et al. Comparison of statin alone versus bezafibrate and statin combination in patients with diabetes mellitus and acute coronary syndrome. Am J Cardiol. 2014;113(1):12-6. doi: 10.1016/j.amjcard.2013.08.033.
39. Teramoto T, Abe K, Taneyama T. Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. Cardiovasc Diabetol. 2013;6(12):163.
40. Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol. 2012;11:140. doi: 10.1186/1475-2840-11-140.